Item 7.01. Regulation FD Disclosure.

On May 9, 2022, Lucid Diagnostics Inc. (the "Company") announced that its wholly-owned CLIA-certified and CAP-accredited laboratory, LucidDx Labs Inc., has entered into a participating provider agreement with MediNcrease Health Plans, LLC, a national, directly-contracted, multi-specialty PPO provider network with over 8 million lives covered through its clients and payers, which include regional and national health plans, insurance companies, third party administrators, self-insured employer groups, municipalities, unions and other entities involved in the management of medical claims. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

The information furnished under this Item 7.01, including the exhibit related thereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits:



Exhibit No.   Description

99.1            Press release.
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses